Anti-PR3 antibodies tested positive in only 5 (1.51% of all LN patients), whereas anti-MPO antibodies were positive in 8 (2.42% of all LN patients) without statistically significant differences between LN groups (p > 0.05 for both). This evidence concerns the gene PRTN3 and lobular neoplasia.